The race for antimicrobials in the multidrug resistance era

The appearance of multidrug‐resistant pathogens is a major threat to human health with the reemergence of fatal and untreatable diseases. In addition to a rational use of the well‐known and available antibiotics, two complementary ways to overcome this public health issue are (i) the discovery of new antimicrobials and (ii) the chemical modification of pre‐existing potent antibiotics. In this article, we highlight some of the strategies to generate new and promising antimicrobials for use in the management of these so‐called ‘superbugs’.

[1]  D. Boger,et al.  Total Synthesis of [Ψ[C(=NH)NH]Tpg4]Vancomycin and its (4-Chlorobiphenyl)methyl Derivative: Impact of Peripheral Modifications on Vancomycin Analogues Redesigned for Dual d-Ala-d-Ala and d-Ala-d-Lac Binding , 2014, Journal of the American Chemical Society.

[2]  G. Wright,et al.  Glycopeptide Antibiotic Resistance Genes in Glycopeptide-Producing Organisms , 1998, Antimicrobial Agents and Chemotherapy.

[3]  D. Boger,et al.  Peripheral modifications of [Ψ[CH2NH]Tpg4]vancomycin with added synergistic mechanisms of action provide durable and potent antibiotics , 2017, Proceedings of the National Academy of Sciences.

[4]  Y. Keynan,et al.  Vancomycin Revisited – 60 Years Later , 2014, Front. Public Health.

[5]  R. Ebright,et al.  Antibacterial Nucleoside-Analog Inhibitor of Bacterial RNA Polymerase , 2017, Cell.

[6]  J. Vila,et al.  Acinetobacter baumannii resistant to everything: what should we do? , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[7]  D. Boger,et al.  Total synthesis and evaluation of [Psi[CH2NH]Tpg4]vancomycin aglycon: reengineering vancomycin for dual D-Ala-D-Ala and D-Ala-D-Lac binding. , 2006, Journal of the American Chemical Society.

[8]  D. Boger,et al.  Total syntheses and initial evaluation of [Ψ[C(═S)NH]Tpg⁴]vancomycin, [Ψ[C(═NH)NH]Tpg⁴]vancomycin, [Ψ[CH₂NH]Tpg⁴]vancomycin, and their (4-chlorobiphenyl)methyl derivatives: synergistic binding pocket and peripheral modifications for the glycopeptide antibiotics. , 2015, Journal of the American Chemical Society.

[9]  J. H. Comroe.  Pay Dirt: The Story of Streptomycin , 2015 .

[10]  W. Farrar,et al.  ‘VANCOMYCIN REVISITED’ , 1978, Annals of internal medicine.

[11]  J. H. Comroe.  Pay dirt: the story of streptomycin. Part I. From Waksman to Waksman. , 1978, The American review of respiratory disease.

[12]  K. Lewis,et al.  A new antibiotic kills pathogens without detectable resistance , 2015, Nature.

[13]  A. Bélanger,et al.  Use of Ichip for High-Throughput In Situ Cultivation of “Uncultivable” Microbial Species , 2010, Applied and Environmental Microbiology.

[14]  D. Boger,et al.  Total synthesis of [Ψ[C(═S)NH]Tpg4]vancomycin aglycon, [Ψ[C(═NH)NH]Tpg4]vancomycin aglycon, and related key compounds: reengineering vancomycin for dual D-Ala-D-Ala and D-Ala-D-Lac binding. , 2012, Journal of the American Chemical Society.

[15]  E. Brown,et al.  Antibacterial drug discovery in the resistance era , 2016, Nature.

[16]  Prateek Shrivastava,et al.  World health organization releases global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics , 2018 .

[17]  Nancy D. Hanson,et al.  Antibacterial-Resistant Pseudomonas aeruginosa: Clinical Impact and Complex Regulation of Chromosomally Encoded Resistance Mechanisms , 2009, Clinical Microbiology Reviews.

[18]  A. Fleming,et al.  On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzæ , 1929 .

[19]  Ramanan Laxminarayan,et al.  Antibiotic effectiveness: Balancing conservation against innovation , 2014, Science.

[20]  A. Fleming,et al.  Classics in infectious diseases: on the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae by Alexander Fleming, Reprinted from the British Journal of Experimental Pathology 10:226-236, 1929. , 1980, Reviews of infectious diseases.

[21]  A. Fleming.  Classics in infectious diseases: on the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae by Alexander Fleming, Reprinted from the British Journal of Experimental Pathology 10:226-236, 1929. , 1980, Reviews of infectious diseases.